Shanghai Henlius Biotech, Inc.
Status: Publicly traded
Direct answer
Shanghai Henlius Biotech, Inc. is publicly traded on HKSE under the ticker 2696.HK.
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia,...
Can you invest in Shanghai Henlius Biotech, Inc.?
Yes. Shanghai Henlius Biotech, Inc. trades publicly on HKSE as 2696.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Shanghai Henlius Biotech, Inc.
Detailed equity research is provided by MarketSnap.